A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
